AAVantgarde Bio is a clinical stage biotechnology company that is developing gene therapies for inherited retinal disorders.
The AAVantgarde cutting-edge gene therapy technology platforms are focused on solving the constraint of oversized gene delivery.
AAVantgarde was co-founded in 2021 by Professor Alberto Auricchio at TIGEM (Telethon Institute of Genetics and Medicine) and Telethon Foundation. The company is headquartered in Milan, Italy.
AAVantgarde has two proprietary, AAV-based large gene delivery platforms: one leveraging DNA recombination, named dual hybrid; and one protein trans-splicing, named AAV intein.
AAVantgarde is validating the platforms in two lead programs: Usher Syndrome Type 1 B associated retinitis pigmentosa (Usher1B), using dual hybrid; and Stargardt disease, using AAV intein.
AAVantgarde has raised €61M ($65.3M) in a Series A round on Jun 06, 2023. The round was co-led by Atlas Venture and Forbion, with participation from Longwood Fund, Sofinnova Partners and Fondazione Telethon.